Carfilzomib 56 mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

References

• Durie B. Concise review of the disease and treatment options: multiple myeloma. North Hollywood: International Myeloma Foundation (IMF); 2018.
   Google Scholar
• MMRF. Multiple myeloma disease overview. Norwalk: Multiple Myeloma Research Foundation; 2017.
   Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091–1114.
   Web of Science ®Google Scholar
• Jakubowiak A. Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy? Semin Hematol. 2012;49(Suppl. 1):S1–S2.
   PubMedGoogle Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–264.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol. 2018;9(7):175–190.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, van de Donk N, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Kyprolis (carfilzomib) summary of product characteristics; 2020 [updated 2020 Jun 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf
   Google Scholar
• U.S. Food and Drug Administration. KYPROLIS (carfilzomib) for injection, for intravenous use; 2020 [updated 2020 Aug]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202714s030lbl.pdf
   Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65–76.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Weisel K, Sonneveld P, Mateos M, et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of castor. Blood. 2019;134(Suppl. 1):3192.
   Google Scholar
• Laws A, Kendall R, Hawkins N. A comparison of national guidelines for network meta-analysis. Value Health. 2014;17(5):642–654.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Huang X, Lu J, Fu W, et al. Phase 3 study of daratumumab/bortezomib/dexamethasone (D-Vd) versus bortezomib/dexamethasone (VD) in Chinese patients (pts) with relapsed/refractory multiple myeloma (RRMM): MMY3009 (LEPUS). Hemasphere. 2020;4:451–452.
   Google Scholar
• Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24(1):29–38.
   PubMed Web of Science ®Google Scholar
• Maiese EM, Ainsworth C, Le Moine JG, et al. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018;40(3):480–494.e23.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Panjabi S, Campioni M, et al. Reframing the value of treatments for relapsed/refractory multiple myeloma. J Manag Care Spec Pharm. 2018;24(7):711–712.
   PubMed Web of Science ®Google Scholar
• Panjabi S, Iskander K. Letter: quest for the best in relapsed/refractory multiple myeloma: a mis-placed endeavor. Clin Ther. 2019;41(1):186–187.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials. PharmacoEconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Majer I, van de Wetering G, Polanyi Z, et al. Panobinostat plus bortezomib versus lenalidomide in patients with relapsed and/or refractory multiple myeloma: a matching-adjusted indirect treatment comparison of survival outcomes using patient-level data. Appl Health Econ Health Policy. 2017;15(1):45–55.
   PubMed Web of Science ®Google Scholar
• Rael M, Benedict A, Ishak J, et al. Indirect comparison to assess the relative efficacy of carfilzomib + lenalidomide + dexamethasone versus bortezomib + thalidomide + dexamethasone: a matching adjusted indirect comparison. Blood. 2015;126(23):5622–5622.
   Web of Science ®Google Scholar
• Van Sanden S, Ito T, Diels J, et al. Comparative efficacy of daratumumab monotherapy and pomalidomide plus low-dose dexamethasone in the treatment of multiple myeloma: a matching adjusted indirect comparison. Oncologist. 2018;23(3):279–287.
   PubMed Web of Science ®Google Scholar
• Weisel K, Majer I, DeCosta L, et al. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Leuk Lymphoma. 2020;61(1):37–46.
   PubMed Web of Science ®Google Scholar
• Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079–2087.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Mateos M-V, Lentzsch S, et al. Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or -refractory patients with relapsed/refractory multiple myeloma (RRMM): analysis of the castor, pollux, and MMY1001 studies. Blood. 2018;132(Suppl. 1):3288.
   Google Scholar
• Phillippo D, Ades T, Dias S, et al. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE; 2016.
   Google Scholar
• Majer IM, Castaigne JG, Palmer S, et al. Modeling covariate-adjusted survival for economic evaluations in oncology. Pharmacoeconomics. 2019;37(5):727–737.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2019;20(8):509–518.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib–melphalan–prednisone in the phase III VISTA study. Am J Hematol. 2015;90(4):314–319.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Oriol A, Martínez-López J, et al. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016;95(12):2033–2041.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11(1):38–43.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010;95(10):1738–1744.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459–3466.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. DARZALEX (daratumumab) summary of product characteristics DARZALEX; 2021 [updated 2021 Nov 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf
   Google Scholar
• U.S. Food and Drug Administration. DARZALEX (daratumumab) injection, for intravenous use; 2021; [updated 2021 Mar; cited 2020 Feb 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761036s033lbl.pdf
   Google Scholar
• Cope S, Toor K, Popoff E, et al. Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma. Value Health. 2020;23(4):441–450.
   PubMed Web of Science ®Google Scholar